TerminatedNCT00768482
Official study titleA Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence
This study ended early.
In Fort LauderdaleAddictionMedication studyAges 18–75
- Countries
- United States
- Sponsor
- Titan Pharmaceuticals
CompletedNCT01177943
Official study titleLY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects
This study has finished and is no longer accepting participants.
In FukuokaADHDMedication studyAges 20–55
- Countries
- Japan
- Sponsor
- Eli Lilly and Company
CompletedNCT00892489
Official study titlePivotal Bioequivalence Study With 15 mg ER OROS Paliperidone Comparing the Phase 3 Formulation With the To-be-marketed Formulation and Evaluation of Food Effect on the to be Marketed Formulation in Healthy Male Subjects
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT05024747
Official study titleA Randomized, Open Label, Single Center, Single Dose, Two Period, Two Sequence Crossover Bioequivalence Study of 21 mg Nicotine Transdermal Patches (NicoDerm CQ, GSK Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
This study has finished and is no longer accepting participants.
In SpringfieldAddictionMedication studyAges 21–55
- Countries
- United States
- Sponsor
- HALEON
CompletedNCT02688374
Official study titleA Single-Dose, Open-Label, Three-way Crossover Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Chinese Male Healthy Adult Smokers
This study has finished and is no longer accepting participants.
In BeijingAddictionInterventional studyAges 18–45
- Countries
- China
- Sponsor
- GlaxoSmithKline
CompletedNCT03541044
Official study titleA Single Dose Bioequivalence Study of a 2 mg Prototype Mini Nicotine Lozenge vs 2 mg Nicotine Mini Lozenge (Nicorette Minis) Healthy Smokers Under Fasting Conditions
This study has finished and is no longer accepting participants.
In LincolnAddictionMedication studyAges 19–55
- Countries
- United States
- Sponsor
- GlaxoSmithKline
UnknownNCT06515522
Official study titleA Biological Signature for the Early Differential Diagnosis of Psychosis: Unveiling the Differences Between Mood Disorders and Schizophrenia With Multimodal Machine Learning Techniques
Current recruitment status is unconfirmed.
Location not clearly listedSchizophrenia, Depression, ...Observational studyAges 18–65
- Countries
- Sponsor
- IRCCS San Raffaele
CompletedNCT05113771
What is this study about?This study evaluated the safety and effectiveness of Liafensine for people with depression.
This study has finished and is no longer accepting participants.
Multiple locations, including HuntsvilleDepressionMedication studyAges 18–70
- Countries
- United States, Canada
- Sponsor
- Denovo Biopharma LLC
CompletedNCT05464121
Official study titleA Blended Intervention for Adjustment Disorder: Feasibility Trial and Preliminary Effectiveness.
This study has finished and is no longer accepting participants.
In CastellonAdjustment disorderBehavioural studyAges 18+
- Countries
- Spain
- Sponsor
- Universitat Jaume I
CompletedEUCTR 2007-004482-18
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In Czech RepublicSchizophreniaHistorical research record
- Countries
- Czechia, Slovakia
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
TerminatedNCT07329621
Official study titleA Phase 1, Open-label, Positron Emission Tomography (PET) Trial to Measure Serotonin 5-HT2A Receptor Occupancy Following Single Oral Doses of MSP-2020 in Healthy Male Adults
This study ended early.
In LondonDepressionMedication studyAges 23–55
- Countries
- United Kingdom
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT07333339
Official study titleComparative Effects of BCI-Based Attention Training, Methylphenidate, and Citicoline on Attention and Executive Function in School-Age Children: A Naturalistic Quasi-Experimental Study
This study has finished and is no longer accepting participants.
In BursaADHDObservational studyAges 6–18
- Countries
- Türkiye
- Sponsor
- Uludag University